Imatinib induced melasma-like pigmentation

Authors

  • Mrinal Gupta

DOI:

https://doi.org/10.66344/jpad.30.2.2020.1395

Abstract

Imatinib mesylate, a tyrosine kinase inhibitor, is used for the treatment of chronic myeloid leukemia (CML), gastrointestinal stromal tumor (GIST), mastocytosis, myelodysplastic and myeloproliferative disorders. Cutaneous side effects of imatinib include xerosis, photosensitivity, pigmentary changes hypopigmentation and rarely hyperpigmentation. A 19-years-old male diagnosed case of CML currently on Imatinib 400mg once daily for 18 months presented with gradually progressive brownish discoloration of face since 6 months. Based on history, clinical features and a temporal association with drug intake, a diagnosis of imatinib-induced melasma-like pigmentation was made and the patient was started on sunscreen and topical depigmenting agents. 

References

Ghunawat S, Sarkar R, Garg VK. Imatinib induced melasma - like pigmentation: Report of five cases and review of literature. Indian J Dermatol Venereol Leprol 2016; 82: 409-12.

Balasubramanian P, Jagadeesan S, Thomas J. Imatinib-induced extensive hyperpigmentation in a case of chronic myeloid leukemia. Indian J Dermatol 2015; 60: 523.

Balagula Y, Pulitzer MP, Maki RG, Myskowski PL. Pigmentary changes in a patient treated with imatinib. J Drugs Dermatol. 2011; 10: 10626.

Alexandrescu DT, Dasanu CA, Farzanmehr H, Kauffman L. Persistant cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST. Dermatol Online J 2008; 14: 7.

Li CC, Malik SM, Blaeser BF, Dehni WJ, Kabani SP, Boyle N, et al. Mucosal pigmentation caused by imatinib: Report of three cases. Head Neck Pathol 2012; 6: 290-5.

Downloads

Published

2020-09-30

How to Cite

1.
Gupta M. Imatinib induced melasma-like pigmentation. J Pak Assoc Dermatol [Internet]. 2020Sep.30 [cited 2026May2];30(2):353-4. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/1395

Issue

Vol. 30 No. 2 (2020): April-June

Section

Case Reports

License

Submission declaration

Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.

By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.